



A

Abacavir (ABC), 29, 35, 335, 336
 adolescent dosing guidelines for, 300, 301
 adverse effects of, 36, 38
 barriers to resistance and, 87
 CNS toxicity and, 248
 dosing of, 60
 lipid changes and, 228
 pediatric dosing guidelines for, 298
 pregnancy and, 278

Abacavir, lamivudine, 30
 adolescent dosing guidelines for, 300, 301
 chemotherapy and, 321
 dosing of, 66

Abacavir, lamivudine, dolutegravir, 67

Abacavir, lamivudine, dolutegravir, cobicistat, 31

Abacavir, lamivudine, zidovudine, 30, 66

Acamprosate, 254

Acetaminophen, 253

Acid-suppressing therapy interactions, 39, 40-41

Acquired resistance, 86

Active tuberculosis, 204
 diagnosis of, 204-205
 treatment of, 207-208

Acute HIV infection
 disease progression and, 6-9
 initial treatment for, 77-79
 signs, symptoms, lab findings in, 8
 typical disease progression of, 8

Acute infection, 27

Acute renal failure, 110

Acyclovir, 140, 156
 genital herpes treatment and, 194
 side effects, toxicities of, 157

Adacavir, pediatric considerations and, 302

Adherence support, 74-75
 importance of, 108
 pediatric, 296-297, 304-305

Adolescent HIV
 adherence support for, 297
 baseline assessments, regimens for, 295, 296
 dosing guidelines for, 300-301
 management of, 291-294
 pre-exposure prophylaxis and, 306
 nPEP and, 117

Adolescent Trials Network, 287

Adriamycin, doxorubicin, bleomycin, vinblastine, dacarbazine, 319

Adverse effects, 35-36. *See also specific drugs.*
 maintenance immunosuppressive agents and, 332-333

AIDS, 9
 defining conditions of, 10

AIDS Clinical Trials Group, 31, 35

AIDS Education & Training Center, 144

AIDSinfo, 143, 144, 145

Alcohol use, 253, 254

Alprazolam, 246

American Academy of HIV Medicine, 22

American Association for the Study of Liver Diseases, 176

American Association of Clinical Endocrinologists, 230

- American Diabetes Association, 230
American Foundation for AIDS Research, 31
Amikacin, 207, 208
Amiodarone, 173
Amitriptyline, 244, 250, 252
Amphetamine use, 255
Amphotericin B, 129
 side effects, toxicities of, 157
Amphotericin B deoxycholate, flucytosine,
 133, 151
Amprenavir, 268
Anal cancer, 317
Anidulafungin IV, 158
Antibody testing, 18-19
Antiretroviral agents, 35
Antiretroviral Pregnancy Registry, 277
Antiretroviral therapy (ART), 25-68, 85-86
 adherence to, 49-50
 discovery of, 28-29
 failure of, 342
 history of, 28-35
 history timeline for, 32-34
 initiating, 214
 switching, 79-80
 toxicity of, 342
Antiretroviral treatment
 goals for, 69
 laboratory monitoring of, 72-74
 pediatric considerations and, 302-303
Antoniou, Tony, 185-202
Anxiety/anxiety-like disorders, 245-247
Archived DNA genotypic assays, 89
Artificial self-insemination, 275
ASPIRE, 111
Atazanavir, 29, 76, 176, 337
 acid suppressing agents and, 40
 adverse effects of, 37-38
 chemotherapy and, 325
 dosing of, 63
 drug interactions and, 211
 pediatric considerations and, 302
 pregnancy and, 278
 renal dysfunction dosing of, 235
Atazanavir, cobicistat (ATV/c), 29, 87
 barriers to resistance and, 87
 dosing of, 63
 renal dysfunction dosing of, 235
Atazanavir, ritonavir (ATV/r)
 adolescent dosing guidelines for, 300, 301
 barriers to resistance and, 87
 lipid changes and, 228
 pediatric dosing guidelines for, 299
 post-exposure prophylaxis, 116
Atovaquone, 130
 side effects, toxicities of, 157
Atripla, 28
AVAC Global Advocacy for HIV Prevention,
 120
Azathioprine, 332, 337
Azithromycin, 153, 187, 189
 side effects, toxicities of, 158
Azithromycin, ethambutol, 136-137, 154
-
- ## B
- Bacterial vaginosis, 191, 192
Badowski, Melissa, 329-340
Bangkok Tenofovir Study, 107
Basiliximab, 331
Belatacept, 332
Benzathine benzylpenicillin, 198, 199
Benzodiazepines, 246, 250
Bias, Tiffany E., 69-83
Bipolar disorder, 249
Bishop, Bryan M., 261-270
Bivalent vaccine (HPV2), 317
Bleomycin, etoposide, doxorubicin,
 cyclophosphamide, vincristine,
 procarbazine, prednisone, 319
Bone health, 236-238
Bone mineral density, 236-237
Bookstaver, P. Brandon, 25-68
Boosted PI plus NRTI regimen failure, 97
British HIV Association, 143, 181
Buprenorphine, 254
-
- ## C
- Caballero, Joshua, 243-260

- Cabotegravir, 112
- Cancer incidence, 314
- Cancer(s), 313-328
 - cART and chemotherapy, 320-322
 - cervical, 315-317
 - colorectal, 319
 - comorbidities evaluation of, 325
 - follow-up plan for, 325-326
 - hepatocellular, 320
 - Hodgkin's lymphoma, 318-319
 - incidence of, 314
 - Kaposi's sarcoma, 313-314
 - non-AIDS-defining, 317-318
 - non-Hodgkins lymphoma, 314-315
 - non-small cell lung, 319-320
- Capecitabine, 322
- Capreomycin, 207, 208
- Capsaicin, topical, 251
- Carbamazepine, 249
- Cardiovascular disease, 226-230
- Care transitions, 341-351
- Casprofungin, IV, 158
- Caulder, Celeste R., 25-68
- CCR5 coreceptor inhibitors, resistance associated with, 93-94
- Cefixime, 189
- Ceftriaxone, 199
- Ceftriaxone, azithromycin, 187, 188
- Cellcept, 332
- Centers for Disease Control and Prevention (CDC), 17-18, 310
 - age-specific staging and, 294
 - HIV epidemiology and, 4-5
 - HIV Prevention, 120
 - HIV Surveillance Report, 13, 282
 - Materials on Medication Adherence, 80
 - National HIV Surveillance System and Medical Monitoring Project, 22
 - Pap screening test and, 317
 - Pre-exposure Prophylaxis Clinical Practice Guideline, 275-276, 282
 - revised testing guidelines, 22
 - testing guidelines by, 19-20
 - tuberculosis, 203
- Cephalosporin, macrolide, 188
- Cerebral toxoplasmosis, 134-135
 - clinical presentation, treatment of, 134
 - primary prevention of, 135
 - treatment of, 134-135, 152
- Cervical cancer
 - invasive, 315-317
 - screening, 281
- Cervicitis, 185-186
- Cha, Agnes, 69-83
- Chemokine receptor 5 (CCR5) antagonists, 28
- Chemotherapy, 320-324, 325-326
 - ART choices for, 323-324
- CHER trial, 295
- Chlamydia, 186-188
- Chlorpromazine, 247
- CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), 315
- Chronic infection, 27
- Chronic kidney disease, 232-236, 329
- Chronic pain, 253
- Cidofovir, 138, 140, 194-195
 - side effects, toxicities of, 158
- Cisplatin, 317, 324
- Citalopram, 244, 245
- Clarithromycin, 153
 - side effects, toxicities of, 158
- Clarithromycin, ethambutol, 136-137, 154
- Clindamycin, 191, 192
 - side effects, toxicities of, 159
- Clindamycin, primaquine, 130
- Clinical Consultation Center, 120
- Clofazimine, 208, 209
- Clonazepam, 246
- Clotrimazole, 129
 - side effects, toxicities of, 159
- Clozapine, 249
- CNS Penetration Effectiveness, 256
- Cobicistat, 30, 75, 176
 - adverse effects of, 37
 - chemotherapy and, 321, 323-324
 - creatinine secretion and, 236
 - dosing of, 66

pregnancy and, 278

Cocaine use, 255

Cocohoba, Jennifer M., 221-241

Cognitive behavioral therapy, 250

Colorectal cancer, 319

Combination antiretroviral therapy (cART), 315, 317. *See also specific therapies*

adolescents and, 291-294

breast feeding and, 291

cancer and, 317, 320-321

chemotherapy and, 320-321, 324-325

HBV and stopping/changing, 169-170

immunosuppressant interactions with, 333-334

pediatric generally, 295-296

pediatric initiation, adherence support with, 296-297

pediatric monitoring of, 297, 303

pediatric regimens of, 296

preventing mother-to-child transmission and, 105

ritonavir or cobicistat containing, 323

treatment as prevention, 103-105

Comprehensive HIV/HCV Drug Therapy and Interaction Guide, 326

Connolly, Kristina E. R., 25-68

Continuum of care, 9, 11

antiretroviral therapy receipt and, 12

engagement in, 12

identifying new cases for, 11

linkage to care and, 11

minimizing medication errors and, 344, 345, 349-350

viral suppression and, 12-13

Contraception

methods, 272-275

safe, 275-276

Coreceptor tropism, 90

Corticosteroids, 333, 337

Covalently closed circular DNA, 165

Cryptococcal meningitis, 132-134

clinical presentation, diagnosis of, 132-133

primary prevention of, 134

treatment of, 133-134, 151

Cyclophosphamide, 322

Cycloserine, 208, 209

Cyclosporine, 175, 331-332, 336-338

Cytomegalovirus disease, 137-139, 326

clinical presentation, diagnosis of, 137-138

esophagitis or colitis and, 155

neurological disease and, 155

primary prevention of, 139

treatment for, 138, 154-155

D

Daclatasvir, ribavirin, 177

Daclatasvir, sofosbuvir, 173, 174, 176

Daclatasvir, sofosbuvir, ribavirin, 174

Dapivirine, 111, 112

Dapsone, 131

side effects, toxicities of, 159

Dapsone, trimethoprim, 130

Darunavir (DRV), 29, 76, 176

adverse effects of, 37, 38-39

dosing of, 63

drug interactions and, 211

pregnancy and, 278

testosterone therapy and, 268

Darunavir, cobicistat (DRV/c), 29

barriers to resistance and, 86

dosing of, 63

renal dysfunction dosing of, 235

Darunavir, ritonavir (DRV/r)

adolescent dosing guidelines for, 300, 301

barriers to resistance and, 87

lipid changes and, 228

pediatric dosing guidelines for, 298

post-exposure prophylaxis and, 116

Dasabuvir, 173, 175-176, 177

Data Collection on Adverse Events of Anti-HIV Drugs study, 163

Delavirdine, 323, 336

Delirium, 247-248

Depot medroxyprogesterone acetate (DMPA), 272, 273

Depression, 243-245

Desensitization protocol, 144

- Dexamethazone, 322
- Diabetes, 231-232
- Diagnosis, 17-23
- Diagnostic testing, principles of, 18-19
- Diazepam, 246
- Didanosine (ddl), 29, 252, 323, 336
 - adverse effects of, 36
 - barriers to resistance and, 87
 - dosing of, 60
 - renal dysfunction dosing of, 234
- Digoxin, 173
- Direct-acting antivirals (DAAs), 171-173, 177, 180
 - drug reaction management of, 178-179
- Disulfiram, 254
- Docetaxel, 322
- Dolutegravir (DTE), 30, 45, 76, 323
 - acid suppressing agents and, 41
 - adolescent dosing guidelines for, 300, 301
 - adverse effects of, 37
 - chemotherapy and, 321
 - containing regimen, barriers to resistance, 87
 - creatinine secretion and, 236
 - dosing of, 65
 - drug interactions and, 210
 - initial regimen advantages/disadvantages of, 78
 - lipid changes and, 228
 - pediatric considerations and, 302
 - pediatric dosing guidelines for, 299
 - transplants and, 337
- Dolutegravir, abacavir, lamivudine, 300, 301
- Donepezil, 248
- Dong, Betty J., 221-241
- Dosing, 60-68
- Doxepin, 250
- Doxorubicin, 314, 322
- Doxycycline, 187, 196, 198, 199
- Drug development, 50-52
- Drug interactions, 45
 - ART and hormonal contraceptives, 273-274
 - chemotherapy, 321-324
 - opportunistic infection drugs and, 144
 - updated assessments and, 45-46
- Drug Resistance Mutation in HIV, 2017 Update, 99
- Drug therapy targets, HIV life cycle, 25-27
- Drug-drug interactions, 39, 334-336
- Drug-food interactions, 46-48
- Duloxetine, 244, 252
-
- ## E
- Echinocandin, IV, 129
- Efavirenz (EFV), 76, 336
 - adverse effects for, 36, 38
 - barriers to resistance and, 87
 - cART, 324
 - chemotherapy and, 322
 - dosing of, 62
 - drug interactions and, 210
 - estrogen therapy and, 268
 - insomnia and, 250
 - lipid changes and, 228
 - pregnancy and, 279
 - testosterone therapy and, 268
- Efavirenz, tenofovir disoproxil fumarate, emtricitabine, 235
- E44D mutation, 92
- Egelund, Eric F., 203-218
- Elbasvir, 173, 175, 177
- Elbasvir/grazoprevir, 174
- Elite controllers, 27
- Elvitegravir (EVG), 30, 39, 76
 - acid suppressing agents and, 41
 - adverse effects of, 37
 - barriers to resistance and, 87
 - initial regimen advantages/disadvantages of, 78
 - major resistance pathways of, 94
 - pediatric considerations and, 303
- Elvitegravir, cobicistat
 - adolescent dosing guidelines for, 300, 301
 - drug interactions and, 210
 - lipid changes and, 229
 - transplants and, 335
- Elvitegravir, cobicistat, tenofovir

alafenamide, emtricitabine, 235

Elvitegravir, cobicistat, tenofovir disoproxil fumarate, emtricitabine

- post-exposure prophylaxis and, 116
- renal dysfunction dosing for, 235

Emtricitabine, 29, 35, 325, 335

- adolescent dosing guidelines for, 300, 301
- adverse effects of, 36
- dosing for, 61
- hepatitis B and, 168
- pediatric considerations and, 302
- PrEP and, 106
- renal dysfunction dosing for, 234

Emtricitabine, tenofovir disoproxil fumarate, 106-108, 109-110, 112

Endocrine Society, The, 263

End-stage liver disease, 329

End-stage renal disease, 329

Enfuvirtide (T-20), 28, 338

- adverse effects of, 37, 39
- barriers to resistance and, 87
- dosing for, 65

Entecavir, 168-169

Enzyme immunoassays, 171

EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), 315

Erythromycin, 196

Escitalopram, 244, 245

Esophageal candidiasis, 127-129

- clinical presentation, diagnosis of, 128-129
- primary prevention of, 129
- treatment for, 129, 148

Estradiol, 265

Eszopiclone, 250

Ethambutol, 207, 208

- side effects, toxicities of, 159

Ethinyl estradiol, 273

Ethionamide, 207, 208, 209

Etonogestrel implants, 273, 274

Etoposide, 322

Etavirine (ETR)

- adverse effects of, 36, 38
- barriers to resistance and, 87

- cART, 324
- dosing of, 62
- drug interactions and, 210
- post-exposure prophylaxis and, 116
- weight factor for resistance-associated mutations, 93

European AIDS Clinical Society, 143-144

European AIDS Treatment Network, 180

Everolimus, 332, 333, 336, 338

F

Famciclovir, 140, 156

- genital herpes treatment and, 194
- side effects, toxicities of, 157

Fanconi's syndrome, 110

FEM-PrEP, 107-108

- 5-fluorouracil, 322

- 5-fluorouracil with mitomycin or cisplatin, 318

FLAMINGO study, 76

Flaviviridae family, 170

Fluconazole, 129, 148

- high-dose, 133, 151

- hormone therapy and, 268

- side effects, toxicities of, 159

Flucytosine PO, side effects, toxicities of, 160

Fluoroquinolones, 189, 207

Fluoxetine, 244, 245

Flurazepam, 250

Foisy, Michelle, 341-351

Food and Drug Administration, rapid testing, 21

Fosamprenavir, 29, 323

- acid suppressing agents and, 40

- adverse effects of, 37, 38-39

- dosing of, 64

- estrogen therapy and, 268

Fosamprenavir, ritonavir, 245

Foscarnet, 138, 154

Foscarnet IV, 140, 194, 195

- side effects, toxicities of, 160

Foscarnet, topical, 194, 195

Fourth generation HIV test, 19-20

Fusion inhibitors, 28

G

Gabapentin, 252
 Galantamine, 248
 Ganciclovir, IV, 138, 154, 155
 side effects, toxicities of, 160
 Garrett, Katy L., 103-123
 G-CSF prophylaxis, 326
 Gender terminology, 262
 Genetic barrier to resistance, 86-87
 Gengraf, 332
 Genital herpes, 192-194
 Genital ulcers, 192-195
 GenoSure Archive, 89
 Genotypic assays, 88-89
 Giguère, Pierre, 163-183
 Glecaprevir, 173, 175, 177
 Glecaprevir, pibrentasvir, 174, 177
 Gonadotropin-releasing hormone (GnRH)
 analogs, 263, 265
 Gonorrhea, 187, 188-189
 Government of Canada, Drugs, 145
 Graham, Kathleen K., 285-311
 Gram stain, 191
 Grazoprevir, 173, 175, 177
 Grochowski, Janet, 85-101
 Guidelines for Prevention and Treatment of
 Opportunistic Infections in HIV-Infected
 Adults and Adolescents, 181
 Guidelines for Use of ARV Agents in Pediatric
 Infection, 295

H

HAART (highly active antiretroviral therapy),
 28
 Haloperidol, 247
 HBV DNA, 167
 HCV Guidance, 182
 Health and Human Services, Department of
 AIDSinfo HIV Drug Database, 80-81
 AIDS Info Website, 80
 cART guidelines, 104
 Hepatic enzyme effects, 39, 42-44
 Hepatitis A, 163-164

 clinical presentation, treatment of, 164
 prevention of, 164
 serology, diagnosis of, 164
 vaccine for, 164
 Hepatitis B, 110, 165-170
 cART stopping/changing, 169-170
 clinical presentation, treatment of,
 167-169
 core antibody, 165
 core antigen, 165
 e antibody, 167
 e antigen, 166
 IRIS and, 169
 prevention of, 168
 serologic test results for, 166
 serology, diagnosis of, 165-167
 surface antibody, 166
 surface antigen, 165
 treatment of, 168
 vaccine for, 168
 virology, replication of, 165
 Hepatitis C, 170-178
 ART treatment options and, 179-180
 chronic, treatment for, 172-174
 clinical presentation of, 171-172
 genotypes and, 170-171
 monitoring of, 177-178
 prevention, reinfection prevention for,
 180
 reactivation of, 177-178
 serology, diagnosis of, 171
 special populations and, 177
 transmission of, 170
 treatment factors with, 176-177
 virology, replication of, 170
 Hepatitis C On-line, 181
 Hepatocellular cancers, 320
 Heroin use, 254
 Herpes zoster, 139-141
 clinical presentation, diagnosis of, 139
 pre-exposure prevention for, 156
 primary prevention for, 140
 treatment of, 140, 156
 Hester, E. Kelly, 271-284

- Hetterman, Elizabeth, 329-340
- High-risk populations/patients, 18, 108, 109
- HIV-1, 3
 - p24 antigen, 18, 19, 20
 - RNA, 18, 19
- HIV-2, 3
- HIV Drug Interactions, 339
- HIV epidemiology, 3-5
- HIV French Resistance, 99
- HIV InSite, 216
- HIV Medicine Association, 22, 140
- HIV Organ Policy Equity (HOPE) Act, 330, 331
- HIV overview, 3-15
- HIV Prevention Trials Network, 103-104, 112, 120
- HIV strains, subtypes, 3
- HIV/AIDS Medical Practice Guidelines, 121
 - on virologic failure, 85
 - Pregnancy and Perinatal Transmission Guidelines, 282
- HIV/HCV Drug Therapy Guide, 144
- HIV-associated neurocognitive disorders (HAND), 247-248
- HIVE, 282
- Hodgkin's lymphoma, 318-319
- Home Access HIV-1 Test System, 21
- Hormonal contraceptives, 272-275
- Hormone therapy, 265-266
- Huesgen, Emily C., 203-218
- Hughes, Christine A., 127-162
- Hypertension, 226
-
- I**
- Ibrahim, Karin, 313-328
- IgG antibodies, 18, 19
 - to hepatitis B core antigen, 165, 166
- Imiquimod, topical, 194
- Immune reconstitution inflammatory syndrome (IRIS), 127, 133, 134, 169
 - tuberculosis and, 214-215
 - uveitis and, 138
- Immunizations, primary care, 224-225
- Immunodeficiency Clinic, University Health Network, Toronto General Hospital, 144, 145
- Immunologic failure, pediatric, 303
- Immunosuppression, 330
- Incomplete virologic response, 85
- Indinavir, 323
 - adverse effects of, 37, 38
 - dosing for, 64
- Indinavir, ritonavir, 29
- Induction agent, 331
- Infectious Diseases Society of America, 176
 - herpes zoster and, 140-141
- Informed consent, general, 18
- INSIGHT START Study Group, 81
- Insomnia, 250-251
- Insomnia Severity Index, 256
- Integrase strand transfer inhibitors (INSTIs), 28-29, 38, 87
 - drug interactions and, 45, 213
 - regimen selection and, 75-76
 - resistance associated with, 93
 - transplantation and, 337
- International Advisory Panel on HIV Care Continuum Optimization, 13-14
- International Antiviral Society—USA, 144
- International Maternal Pediatric and Adolescent AIDS Clinical Trials, 287
- IPERGAY study, 108
- iPrEx*, 106, 107
- Isoniazid, 206-207, 208
- Itraconazole, 133, 151
 - cART and, 325
 - hormone therapy and, 268
 - oral, 129, 148
 - side effects, toxicities of, 159
 - solution, 129
-
- J**
- Jarisch-Herxheimer reaction, 198
- Joint United Nations Programme on HIV/AIDS, 3, 14
-
- K**
- Kanamycin, 207, 208

Kaposi's sarcoma, 313-314
 Kashuba, Angela DM, 103-123
 Kelly, Deborah V., 185-202
 K103N mutation, 91
 Kreuzwiser, Denise, 163-183
 K65R mutation, 91, 92

L

Lamivudine (3TC), 28, 29, 35, 325, 335
 adolescent dosing guidelines for, 300, 301
 adverse effects of, 36
 barriers to resistance and, 87
 dosing of, 61
 hepatitis B and, 168, 169
 pediatric considerations and, 302
 pediatric dosing guidelines for, 298
 renal dysfunction dosing for, 234
 Lamivudine, zidovudine, 66
 Lamotrigine, 249, 252
 Latent tuberculosis infection, 204
 diagnosis of, 205-206
 screening for, 206
 treatment of, 206
 Ledipasvir, 172-174
 Ledipasvir/sofosbuvir, 174
 Levofloxacin, 207, 208
 side effects, toxicities of, 160
 Lidocaine, 251
 Linezolid, 209
 Lithium, 249
 Long-term nonprogressors, 27
 Lopinavir, 211
 Lopinavir, ritonavir, 190
 adverse effects of, 37, 38
 barriers to resistance and, 87
 dosing of, 64
 lipid changes and, 228
 pediatric considerations for, 302
 pediatric dosing guidelines for, 299
 post-exposure prophylaxis and, 116
 renal dysfunction dosing, 235
 Lorazepam, 246, 247
 Low-level viremia, 86

L74V mutation, 91, 92
 Lymphogranuloma venereum, 195-196

M

Macrolides, 189
 Maraviroc (MVC), 28, 30
 adverse effects of, 37, 39
 barriers to resistance and, 87
 cARTm 324
 dosing of, 65
 interactions with, 45
 renal dysfunction dosing of, 235
 transplants and, 338
 Marijuana, 252, 253, 254
 Medication errors, 341-342
 community/ambulatory setting
 minimization of, 344-345, 346-347,
 350
 correctional facilities minimization of,
 345, 347-348
 hospital setting minimization of, 342-344
 Melatonin, 250
 Memantine, 248
 Mental health
 disorders in transgender patient, 261,
 263-264
 neuropsychiatric disorders and, 243-251
 Mental illness, severe, 248-249
 Metformin, 45
 Methadone, 254
 Methotrexate, 324
 Methylenedioxymethamphetamine (MDMA),
 255
 Metronidazole, 190, 191, 192
 Miconazole IV, side effect toxicities, 158
 Miconazole mucoadhesive buccal tablets, 129
 Microbicide Trials Network, 112, 120
 Minocycline, 248
 Mirtazapine, 244-245, 250
 M184V mutation, 90-91, 92
 Monoclonal antibodies, 51, 112
 Morbidity increase, 342
 Mother-to-child transmission, 272, 277-278,
 280, 285, 286

preventing, 105
Motivational interviewing, 74-75
Moxifloxacin, 209
 side effects, toxicities of, 160
Multicenter AIDS Cohort Study, 167
Multiclass resistance, pediatric, 303-305
Multispot test, 20
Mycobacterium avium complex disease,
 135-136, 325-326
 clinical presentation, diagnosis of, 136
 pediatric preventions for, 306, 307-308
 primary preventions for, 137
 treatment of, 136-137, 153-154
Mycophenolate mofetil, 331, 332
 solid organ transplantation and, 335
Mycophenolic acid with glucocorticoid, 331
Myfortic, 332

N

Naltrexone, 254
National Association of Crime Victim
 Compensation Boards, 120
National Center for Transgender Equality,
 269
National Clinician's Consultation Center,
 state laws, 22
National Institute of Allergy and Infectious
 Diseases, 31, 35
National LGBT Health Education Center, 269
National Perinatal HIV Consultation and
 Referral Service, 282
National Perinatal HIV Hotline, 310
National Resource on Youth and HIV, 310
Nelfinavir, 323
 acid suppressing agents and, 40
 adverse effects of, 37, 38
 dosing of, 64
Neoral, 332
Neurocognitive disorders, 247-248
Neuropathy, 251, 252
Neuropsychiatric disorders, 243-260
 mental health and, 243-251
Nevirapine (NVP), 28, 29, 210, 336
 adverse effects of, 36, 38
 barriers to resistance and, 87
 cART and, 324
 chemotherapy and, 322
 dosing of, 62
 estrogen therapy and, 268
 infant dosing of, 290
 testosterone therapy and, 268
New York State Department of Health
 AIDS Institute, 200
 HIV Testing Toolkit, 22
Nitroimidazoles, 190
Non-AIDS-defining cancers, 317-318
Non-Hodgkin's lymphoma, 314-315
Nucleoside reverse transcriptase
 inhibitors (NNRTIs), 27, 29
 adverse effects of, 38
 drug interaction for, 209, 212
 plus dual NRTI regimen failure, 97
 regimen selection for, 76
 resistance associated with, 91
 solid organ transplant and, 336-337
Nonoccupational exposure, 6
Non-occupational post-exposure prophylaxis
 (nPEP), 114, 115-117, 119
 evaluation/treatment algorithm for, 118
Non-small cell lung cancer, 319-320
Nonsteroidal anti-inflammatory drug
 (NSAID), 252-253
Norethindrone, 274
Norgestimate, 273
Nucleic acid amplification tests (NAATs),
 186, 188
Nucleoside reverse transcriptase inhibitors
 (NRTIs), 27, 29
 adverse effects of, 35-36, 38
 barriers to resistance and, 87
 drug interactions of, 212
 solid organ transplant and, 335-336
 regimen selection of, 75
 resistance associated with, 90-91, 92
Nystatin, 129
 side effects, toxicities of, 160

O

Obitasvir, 173
 Occupational exposure, 6, 114, 115
 Office for Victims of Crime People, 120
 Olanzapine, 249
 Ombitasvir, 175-176, 177
 Omeprazole, 337
 Opioid use disorder, 254
 Opioids, 253
 Opportunistic infections, 127-162

- drug access for, 146
- patient education about, 146
- pediatric prevention of, 305-306
- therapy side effects, toxicities of, 157-162
- treatments for, 143-144

 Oraquick Advance Rapid HIV Test, 21
 OraQuick In-Home HIV Test, 21
 Oropharyngeal candidiasis, 127-128

- clinical presentation, diagnosis of, 128
- primary prevention for, 129
- treatment of, 129, 148

 Oxazepam, 246
 Oxycodone, 254

P

Paclitaxel, 314
 Pain, 251-253
 Panel on Antiretroviral Guidelines for Adults and Adolescents, 216, 339
 Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, 216
 Pap test, 315, 318
 Para-aminosalicylic acid, 209
 Parenteral drugs, 253
 Parenteral exposure, 7

- risk of, 115

 Paritaprevir, 173
 Paritaprevir, ritonavir, 175, 177
 Paritaprevir, ritonavir, ombitasvir, dasabuvir, 175-176
 Paroxetine, 244, 245
Partners PrEP, 106-107
 Partnership for Prescription Assistance, 121
 Patient assessment, baseline, 70-71
 Patient education, opportunistic infection drugs, 146
 Patient Health Questionnaire (PHQ-9), 256
 Patient management, failed first-line ARV regimen, 97
 Pediatric AIDS Clinical Trials Group, 285, 288
 Pediatric HIV, 285-311

- adherence strategies for, 304-305
- ART considerations in, 302
- baseline assessments for, 295
- challenges in, 287
- dosing guidelines for, 298-299
- immune system staging, viral load and, 294-295
- management of, 291, 292-293
- monitoring treatment, comorbidities, 297-298
- multiclass resistance in, 303-304
- neonatal post-exposure prophylaxis in, 288
- nonperinatally acquired, 285, 287
- nPEP and, 117
- opportunistic infection preventions for, 305-308
- perinatally acquired, 285, 286
- symptoms of, 295
- testing neonates for, 287-288
- testing, transmission prevention of, 306
- treatment failure and, 303
- treatment initiation, adherence support in, 296-297
- vaccines and, 305-306

 Peg-interferon alfa monotherapy, 169
 Pegylated interferon, ribavirin, 177
 Penicillin G, 199
 Pentamidine IV/for inhalation, 161
 Pérez, Sarah E., 329-340
 Perinatal transmission, 6
 Pharmacist's role

- for cancer patient, 326
- for transgender patient, 266-267, 268-269
- for transplants, 338
- for viral hepatitis patients, 180-181
- in adherence, 75, 80

- in ART, 53-54
 - in continuum of care, 13
 - in coordinating patient care, 348
 - in HIV testing, diagnosis, 21-22
 - in neuropsychiatric disorders, 255-256
 - in opportunistic infections, 141-142
 - in pediatric HIV, 309-310
 - in primary care, 238
 - in sexually transmitted infection
 - screening, treatment, 199-200
 - in transmission, 119-120
 - in tuberculosis treatment, 215
 - in virologic failure management, 98-99
 - in women's health, 281-282
 - Pharmacokinetic enhancers, 39
 - Phenotypic assays, 89
 - Pibrentasvir, 173, 175, 177
 - Picornavirus, 163
 - PK enhancer interactions, 44
 - Pneumocystis jirovecii* pneumonia, 130, 325
 - clinical presentation, diagnosis of, 130
 - pediatric prevention for, 306, 307-308
 - prevention, treatment in infants of, 291
 - primary prevention for, 132
 - treatment for, 130-131, 148-150
 - Polymerase chain reaction, 193
 - Posaconazole, 129, 133
 - Post-exposure prophylaxis (PEP), 114-116, 117
 - preferred, alternative regimens for, 116, 117
 - Preconception counseling, 271-272
 - Prednisolone, 322
 - Pre-exposure prophylaxis (PrEP), 106, 275-276
 - adherence importance and, 108
 - cost of, 111
 - development pipeline for, 113
 - evidence for, 106
 - FTC/TDF alternatives and, 111-112
 - future studies for, 112
 - indications/target populations for, 108-109
 - monitoring, 109-110
 - pediatric HIV and, 306
 - successful program for, 110-111
 - Pregnancy, PrEP and, 110
 - PrEPWatch, 121
 - Prevention, 103-123
 - demographics of, 103-104
 - post-exposure prophylaxis and, 114-116
 - pre-exposure prophylaxis and, 106-113
 - preventing mother-to-child, 105, 106
 - prevention of, 103-123
 - treatment as prevention and, 103-105, 106
 - Primaquine PO, 161
 - Primaquine, clindamycin, 130
 - Primary care, 221-241
 - immunizations and, 224-225
 - initial visit for, 221-223
 - of chronic comorbid conditions, 226-238
 - routine laboratory tests for, 223
 - Progestin-only oral contraceptives, 273
 - Prograf, 332
 - Protease inhibitors (PIs), 27-28, 175
 - adverse effects of, 38-39
 - chemotherapy and, 321
 - drug interactions and, 212-213, 337
 - regimen selection and, 75
 - resistance associated with, 91
 - Proton pump inhibitors, 336-337
 - Puga, Ana M., 285-311
 - Pyrazinamide, 207, 208, 209
 - Pyrimethamine PO, 161
 - Pyrimethamine, clindamycin, leucovorin, 135
-
- Q**
- Q151M complex mutation, 92
 - Quadrivalent vaccine (HPV4), 316-317
 - Quazepam, 250
 - Quetiapine, 249
-
- R**
- Rabbit antithymocyte globulin (rATG), 331
 - Raltegravir (RAL), 28, 30, 75, 76, 323
 - acid suppressing agents and, 41

- adverse effects of, 37
 - barriers to resistance, 87
 - CNS and, 248
 - dosing of, 65
 - drug interactions of, 210
 - initial regimen advantages/disadvantages for, 79
 - lipid changes and, 228
 - major pathways of resistance, 94
 - pediatric considerations and, 302
 - pediatric dosing guidelines for, 299
 - post-exposure prophylaxis, 116
 - pregnancy and, 278-279
 - transplants and, 337
 - Raltegravir, tenofovir disoproxil fumarate, emtricitabine, 116
 - Rapamune, 333
 - Rapid plasma reagin tests, 197
 - Rapid progressors, 27
 - Rapid testing, 20-21
 - Recent infection, 77
 - Recommendations on Treatment of Hepatitis C, 182
 - Regimen selection, 75-77
 - Resistance
 - by antiretroviral class, 90-94
 - genetic barriers to, 86
 - mutations and, 87-88
 - principles of, 86
 - testing, 88-90, 95
 - R5-tropic strains, 93-94
 - Ribavirin, 176, 177
 - Rifabutin, 208
 - PO, side effects, toxicities of, 161
 - Rifampin, 175
 - drug interactions and, 209-213
 - hormone therapy and, 268
 - Rifamycin, 209
 - Rifapentine, 207, 208
 - drug interactions and, 209-213
 - Rilpivirine (RPV), 323
 - acid suppressing agents and, 40
 - adverse effects of, 36, 38
 - barriers to resistance and, 87
 - chemotherapy and, 325
 - dosing of, 63
 - drug interactions and, 211
 - lipid changes and, 228
 - pregnancy and, 279
 - PrEP and, 112
 - proton pump inhibitors and, 336-337
 - Rilpivirine, creatinine secretion and, 236
 - Rilpivirine, tenofovir alafenamide, emtricitabine, 236
 - Rilpivirine, tenofovir disoproxil fumarate, emtricitabine, 236
 - Ring Study, The, 111
 - Risperidone, 249
 - Ritonavir, 28, 30, 75, 173, 175-177, 190
 - adverse effects of, 37
 - boosted atazanavir, 38
 - boosted darunavir, 38
 - boosted lipid changes, 228
 - alprazolam and, 246-247
 - bupropion and, 245
 - chemotherapy and, 323-324
 - dosing of, 66
 - testosterone therapy and, 268
 - Rituximab, 315, 316
 - Rivastigmine, 248
 - Rosuvastatin, 173
-
- S**
- Saber, Parya, 85-101
 - SandIMMUNE, 332
 - Saquinavir, 28, 323
 - adverse effects of, 37, 38
 - dosing of, 64
 - Schafer, Jason J., 17-23
 - Schizophrenia, 249
 - Screening, opting in or out, 17-18
 - Selective serotonin reuptake inhibitors, 244
 - Serotonin norepinephrine reuptake inhibitors, 244-245
 - Sexual exposure, 7
 - risk of, 115
 - Sexually Transmitted Diseases Treatment Guidelines (CDC), 200

Sexually transmitted infections, 185-202
 routine screening for, 185
 urethritis, cervicitis and, 185-189
 vaginal, urethral discharge and, 189-192

Sherman, Elizabeth M., 3-15

Simeprevir, 176

Simeprevir, sofosbuvir, 173, 176

Sirolimus, 332, 333, 336

Sofosbuvir, 172-175

Sofosbuvir, ledipavir, 177

Sofosbuvir, ribavirin, 177

Sofosbuvir, velpatasvir, 177

Sofosbuvir, velpatasvir, voxilaprevir, 174

Solid organ transplantation, 329-340
 cART and immunosuppressant interactions in, 333-334
 epidemiology of, 329-330
 HIV patients and, 330
 immunosuppression and, 330
 induction agent and, 331
 infections and, 338
 maintenance and, 331-332

Spirolactone, 268

Stanford University HIV Resistance Database, 99

Start Free, Stay Free AIDS Free Initiative, 285

START trial, 69, 77, 104-105, 295

STARTMARK study, 76

Statin interactions, 44

Stavudine (d4T), 29, 252, 322, 323, 336
 adverse effects of, 36
 barriers to resistance and, 87
 dosing of, 61
 renal dysfunction dosing for, 234

Streptomycin, 207, 208

Suboptimal CD4+ cell count response, 86

Substance use disorders, 253-255

Sulfadiazine, pyrimethamine, leucovorin, 134-135, 152, 162

Sulfamethoxazole/trimethoprim, 268, 325
 IV/PO, side effects, toxicities of, 162

Supportive therapy, 325

Suppression management, 89

Syphilis, 196-199

T

Tacrolimus, 331-332, 336, 337

Temazepam, 246, 250, 251

TEMPRANO study, 69-70, 77
 ANRS 12136 Study Group, 81

Tenofovir, 173, 325
 adolescent dosing guidelines for, 300, 301
 -cART, 324
 CNS and, 248
 PrEP and, 106

Tenofovir alafenamide (TAF), 29, 44-45, 335-336
 adverse effects of, 36
 barriers to resistance, 87
 chemotherapy and, 321, 324
 drug interactions and, 211
 hepatitis B and, 168
 pediatric considerations for, 302

Tenofovir alafenamide fumarate, emtricitabine, 30
 adolescent PrEP and, 306
 dosing of, 66
 lipid changes and, 228
 renal dysfunction dosing of, 234

Tenofovir alafenamide fumarate, emtricitabine, rilpivirine, 31
 dosing, 67, 68

Tenofovir disoproxil fumarate (TDF), 29, 44-45, 335-336
 acute renal failure and, 110
 adverse effects of, 36
 barriers to resistance and, 87
 chemotherapy and, 321
 dosing of, 62
 drug interactions and, 211
 hepatitis B and, 168, 169
 lipid changes and, 228
 pediatric considerations and, 302
 pregnancy and, 278, 279
 PrEP and, 106-110

Tenofovir disoproxil fumarate, emtricitabine, 31, 275-276
 adolescent PrEP and, 306
 dosing of, 67

- lipid changes and, 228
- post-exposure prophylaxis and, 116
- renal dysfunction dosing for, 234
- transgender patient and, 268
- Tenofovir disoproxil fumarate, emtricitabine, darunavir, 117
- Tenofovir disoproxil fumarate, emtricitabine, dolutegravir, 79, 117
- Tenofovir disoproxil fumarate, emtricitabine, efavirenz, 28, 31
 - dosing of, 67
- Tenofovir disoproxil fumarate, emtricitabine, elvitegravir, cobicistat, 31
 - dosing of, 67
- Tenofovir disoproxil fumarate, emtricitabine, raltegravir, 117
- Tenofovir disoproxil fumarate, emtricitabine, ritonavir, 117
- Tenofovir disoproxil fumarate, emtricitabine, ritonavir-boosted darunavir, 79
- Tenofovir disoproxil fumarate, lamivudine, 116
- Terminal infection, 27
- Testing, 17, 17-23
 - at-home, 21
 - rapid, 20-21
 - repeat, 18
- Testosterone, 266, 268
- Therapeutic drug monitoring
 - laboratories and, 216
 - tuberculosis and, 213-214
- Third-generation immunoassays, 19
- Thomas, Jennifer E., 243-260
- Thymidine analogue associated mutations (TAMs), 90, 92
- Thyroid dysfunction, 230-231
- Tinidazole, 190, 191, 192
- Tipranavir, 30
 - acid suppressing agents and, 40
 - adverse effects of, 37, 39
 - dosing of, 64
 - testosterone therapy and, 268
- Toronto General Hospital & Ottawa Hospital HIV and HCV Drug Therapy Guide, 182
- Toxicity monitoring, 297, 303
- Toxoplasma encephalitis, pediatric
 - prophylaxis, 307-308
- Transgender patient care, 261-270
 - health issues in, 261, 263-264
 - HIV care in, 267-268
 - medications used for, 264-266
 - other considerations in, 266-267
 - treatment and, 263
- Transmission prevention, 5-6, 17, 103-123
 - demographics of, 103-104
 - post-exposure prophylaxis and, 114-116
 - pre-exposure prophylaxis and, 106-113
 - preventing mother-to-child, 105, 106
 - prevention of, 103-123
 - treatment as prevention and, 103-105, 106
- Transmitted resistance, 86
- Transplantation, 329-340. *See also* Solid Organ Transplantation
 - cART and immunosuppressant interactions in, 333-334
 - epidemiology of, 329-330
 - HIV patients and, 330
 - immunosuppression and, 330
 - induction agent and, 331
 - infections and, 338
 - maintenance and, 331-332
- Trazodone, 250
- Treatment as prevention (TaSP), 103-105
- Treatment failure management
 - first line, 97-98
 - new regimen introduction and, 96
 - of multiple regimens, 98
 - pediatric, 303
 - resistance and, 85-101
 - selecting new regimen for, 95-96
 - syphilis and, 197-198
 - terminology in, 85-86
- Treatment history, 95
- Treatment initiation, 69-74
 - pediatric, 296-297
 - prior to, 71
 - recommendations for, 69-70
 - recommended regimens for, 76
 - regimen advantages/disadvantages in, 78

- Treatment regimen
 - follow-up, monitoring of, 96
 - patient management of failed first-line, 97
 - Trichomoniasis, 189-190, 192
 - Tricyclic antidepressants, 244
 - Trimethoprim PO, 162
 - Trimethoprim-sulfamethoxazole (TMP-SMX)
 - 39, 130, 131, 135, 149-150, 152
 - Tropism assays, 90
 - Tseng, Alice L., 125, 163-183
 - T69 insertion, 92
 - Tuberculosis, 203-218
 - drug interactions and, 209-212
 - epidemiology of, 203
 - IRIS and, 214-215
 - microbiology of, 204
 - testing for, 206
 - therapeutic drug monitoring and, 213-214
 - transmission, infection control of, 204
-

U

- U.S. Preventive Services Task Force, 17-18
 - Uni-Gold Recombigen HIV test, 21
 - United Nations
 - AIDS website, 310
 - Programme on HIV/AIDS (UNAIDS), 104
 - University of Liverpool
 - Hepatitis Drug Interaction Checker, 182
 - HIV Pharmacology, 144
 - Urethral discharge, 189-192
 - Urethritis, 185-186
-

V

- V1181 mutation, 92
- Vaccines, 51-53
 - pediatric, 305-306
- Vaginal discharge, STIs, 189-192
- Valacyclovir, 140, 156
 - genital herpes treatment and, 194
 - side effects, toxicities of, 157
- Valganciclovir PO

- side effects, toxicities of, 160
 - oral, 138, 154, 155
 - Velpatasvir, 173-175
 - Velpatasvir, sofosbuvir, 173-174
 - Venereal Disease Research Laboratory tests, 197
 - Venlafaxine, 244
 - Vinblastine, 322
 - Vinca-alkaloids, 322
 - Vincristine, 322
 - Viral blips, 85, 97
 - Viral hepatitis, 163-183
 - Viral Hepatitis Information, 181
 - Viral load
 - pediatric, 294-295
 - suppressed, 103-104, 105
 - Viral set point, 9
 - Viral steady-state, 9
 - Viremia, 97
 - Virologic failure, 85
 - causes of, 94-95
 - pediatric, 303
 - Virtual phenotypes, 89-90
 - VOICE, 107-108, 111
 - V1181 mutation, 92
 - Voriconazole, 133
 - cART and, 325
 - IV/PO, 129, 159
 - Voxilaprevir, 174-175
 - Voxilaprevir, velpatasvir, 174
 - Voxilaprevir, velpatasvir, sofosbuvir, 176, 177
-

W

- WAVES trial, 76
- Western blot test, 19
- Window period, 19
- Women's health, 271-284
 - antepartum management for, 277-278
 - ART in pregnancy and, 278-279
 - cervical cancer screening and, 281
 - gender differences and, 271
 - intrapartum management for, 280
 - postpartum management for, 280-281

preconception counseling for, 271-272
pregnancy care for, 277
safe conception for, 275-276
Wong, Alison Yi Jin, 313-328
World Health Organization (WHO), 144
 cART guidelines by, 104
 HIV link, 121
 on tuberculosis, 203
World Professional Association for
 Transgender Health, 263
Worley, Marylee, 3-15

Y

Y181C mutation, 91
Yoong, Deborah, 127-162

Z

Zaleplon, 250, 251
Zidovudine (AZT), 28-29, 336
 adverse effects of, 36
 barriers to resistance, 87

 chemotherapy and, 322, 324
 CNS toxicity and, 248
 dosing of, 62
 neonatal dosing of, 288-290
 pediatric considerations for, 302
 pediatric dosing guidelines for, 299
 renal dysfunction dosing of, 234
Zidovudine, emtricitabine, 116
Zidovudine, lamivudine, darunavir, 117
Zidovudine, lamivudine, dolutegravir 117
Zidovudine, lamivudine, lopinavir, 117
Zidovudine, lamivudine, nevirapine, 290
Zidovudine, lamivudine, raltegravir, 117
Zidovudine, lamivudine, ritonavir, 117
Zolpidem, 250, 251
Zortress, 333
Zung Self-Rated Anxiety Scale, 256

